Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
Background Mesenchymal stem cells (MSCs)-based therapy has shown promising results for renal injury. In this study, the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating nonspecific interstitial fibrosis and tubular atrophy (IFTA) were evaluated. Meth...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Renal Failure |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/0886022X.2021.1968432 |
id |
doaj-773d8bde23544958936dea6dc8e14d07 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lei Zhang Xingqiang Lai Yuhe Guo Junjie Ma Jiali Fang Guanghui Li Lu Xu Wei Yin Zheng Chen |
spellingShingle |
Lei Zhang Xingqiang Lai Yuhe Guo Junjie Ma Jiali Fang Guanghui Li Lu Xu Wei Yin Zheng Chen Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study Renal Failure interstitial fibrosis and tubular atrophy mesenchymal stem cells chronic allograft nephropathy renal function |
author_facet |
Lei Zhang Xingqiang Lai Yuhe Guo Junjie Ma Jiali Fang Guanghui Li Lu Xu Wei Yin Zheng Chen |
author_sort |
Lei Zhang |
title |
Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study |
title_short |
Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study |
title_full |
Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study |
title_fullStr |
Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study |
title_full_unstemmed |
Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study |
title_sort |
autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study |
publisher |
Taylor & Francis Group |
series |
Renal Failure |
issn |
0886-022X 1525-6049 |
publishDate |
2021-01-01 |
description |
Background Mesenchymal stem cells (MSCs)-based therapy has shown promising results for renal injury. In this study, the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating nonspecific interstitial fibrosis and tubular atrophy (IFTA) were evaluated. Methods From March 2011 to January 2013, 11 renal transplanted patients with IFTA were recruited. At baseline, patients were given one intra-arterial infusion of BM-MSCs; 7 days and 1 month later, another two intravenous infusions of cells were followed. Serum creatinine, creatinine clearance rate, and serum cystatin-C at baseline and 7 days, 1 month, 3 months, 6 months, and 12 months after the intra-arterial infusion of BM-MSCs were used to assess renal function. At baseline and 6 months, histological examination based on hematoxylin-eosin, Masson’s trichrome and periodic acid-Schiff staining and immunohistochemistry for transforming growth factor β1 (TGF-β1) and connective tissue growth factor (CTGF) was performed. Adverse events were recorded to evaluate the safety of BM-MSCs treatment. Results At 12 months, the renal function of 6 patients (54.5%) was improved, 3 (27.3%) were stable and 2 (18.2%) were worsened. At 6 months, the mean IFTA scores of all participators were similar with the baseline (1.73 ± 0.41 vs.1.50 ± 0.0.77, p = 0.242); however, it was significantly decreased when only 6 patients with improved renal function were analyzed (1.67 ± 0.41 vs. 1.08 ± 0.20, p = 0.013). Besides, decreased expression of TGF-β1 and CTGF were also observed at 6 months. During 1 year follow-up period, only two minor complications including infection and allergy were observed. Conclusion Our results demonstrated that autologous BM-MSCs are safe and beneficial for IFTA patients. Abbreviations: MSCs: mesenchymal stem cells; BM-MSCs: marrow-derived mesenchymal stem cells; IFTA: interstitial fibrosis and tubular atrophy; CAN: chronic allograft nephropathy; CNIs: calcineurin inhibitors; Scr: serum creatinine; CCr: creatinine clearance rate; Cys-C: cystatin-C; TGF-β1: transforming growth factor β1; CTGF: connective tissue growth factor |
topic |
interstitial fibrosis and tubular atrophy mesenchymal stem cells chronic allograft nephropathy renal function |
url |
http://dx.doi.org/10.1080/0886022X.2021.1968432 |
work_keys_str_mv |
AT leizhang autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT xingqianglai autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT yuheguo autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT junjiema autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT jialifang autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT guanghuili autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT luxu autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT weiyin autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy AT zhengchen autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy |
_version_ |
1717374516508753920 |
spelling |
doaj-773d8bde23544958936dea6dc8e14d072021-09-20T12:43:20ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492021-01-014311266127510.1080/0886022X.2021.19684321968432Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot studyLei Zhang0Xingqiang Lai1Yuhe Guo2Junjie Ma3Jiali Fang4Guanghui Li5Lu Xu6Wei Yin7Zheng Chen8Department of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityDepartment of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University/The Second Clinical Medicine School of Guangzhou Medical UniversityBackground Mesenchymal stem cells (MSCs)-based therapy has shown promising results for renal injury. In this study, the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating nonspecific interstitial fibrosis and tubular atrophy (IFTA) were evaluated. Methods From March 2011 to January 2013, 11 renal transplanted patients with IFTA were recruited. At baseline, patients were given one intra-arterial infusion of BM-MSCs; 7 days and 1 month later, another two intravenous infusions of cells were followed. Serum creatinine, creatinine clearance rate, and serum cystatin-C at baseline and 7 days, 1 month, 3 months, 6 months, and 12 months after the intra-arterial infusion of BM-MSCs were used to assess renal function. At baseline and 6 months, histological examination based on hematoxylin-eosin, Masson’s trichrome and periodic acid-Schiff staining and immunohistochemistry for transforming growth factor β1 (TGF-β1) and connective tissue growth factor (CTGF) was performed. Adverse events were recorded to evaluate the safety of BM-MSCs treatment. Results At 12 months, the renal function of 6 patients (54.5%) was improved, 3 (27.3%) were stable and 2 (18.2%) were worsened. At 6 months, the mean IFTA scores of all participators were similar with the baseline (1.73 ± 0.41 vs.1.50 ± 0.0.77, p = 0.242); however, it was significantly decreased when only 6 patients with improved renal function were analyzed (1.67 ± 0.41 vs. 1.08 ± 0.20, p = 0.013). Besides, decreased expression of TGF-β1 and CTGF were also observed at 6 months. During 1 year follow-up period, only two minor complications including infection and allergy were observed. Conclusion Our results demonstrated that autologous BM-MSCs are safe and beneficial for IFTA patients. Abbreviations: MSCs: mesenchymal stem cells; BM-MSCs: marrow-derived mesenchymal stem cells; IFTA: interstitial fibrosis and tubular atrophy; CAN: chronic allograft nephropathy; CNIs: calcineurin inhibitors; Scr: serum creatinine; CCr: creatinine clearance rate; Cys-C: cystatin-C; TGF-β1: transforming growth factor β1; CTGF: connective tissue growth factorhttp://dx.doi.org/10.1080/0886022X.2021.1968432interstitial fibrosis and tubular atrophymesenchymal stem cellschronic allograft nephropathyrenal function |